Chimeric Therapeutics licenses CAR-T therapy from the University of Pennsylvania

July 29, 2021 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has entered into an exclusive licensing agreement with the University of Pennsylvania for the CDH17 chimeric antigen receptor T cell therapy. …

Subscribe now to continue reading.

Latest Video

Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - Latest News
Australian approval for AstraZeneca's near‑zero global warming propellant inhaler
July 22, 2026 - Latest News
If this is an example of a bully playing hardball, it's not the companies
July 21, 2026 - Latest News
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - Latest News
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - Latest News

Chimeric Therapeutics licenses CAR-T therapy from the University of Pennsylvania

This is a preview of subscriber content

Latest Video

Most Read

Major brands and biosimilars feature prominently on November PBAC agenda

Australian approval for AstraZeneca's near‑zero global warming propellant inhaler

If this is an example of a bully playing hardball, it's not the companies

Faster processes could push Pharmac's options for investment backlog to 400 within two years

How national HPV vaccination programs are changing the story of cervical cancer

New Stories

Finalists named for the 2026 Patient's Choice awards

Australian company moving headquarters to US and restructuring workforce

The 'end of days' language is just a farcical attempt to shut down discussion

How national HPV vaccination programs are changing the story of cervical cancer

Faster processes could push Pharmac's options for investment backlog to 400 within two years

Bellberry and ASCEPT release checklist for 'new approach methodologies' trials

Major brands and biosimilars feature prominently on November PBAC agenda

Sign In

Chimeric Therapeutics licenses CAR-T therapy from the University of Pennsylvania

This is a preview of subscriber content

Latest Video

Most Read

Major brands and biosimilars feature prominently on November PBAC agenda

Australian approval for AstraZeneca's near‑zero global warming propellant inhaler

If this is an example of a bully playing hardball, it's not the companies

Faster processes could push Pharmac's options for investment backlog to 400 within two years

How national HPV vaccination programs are changing the story of cervical cancer

Follow Us

New Stories

Finalists named for the 2026 Patient's Choice awards

Australian company moving headquarters to US and restructuring workforce

The 'end of days' language is just a farcical attempt to shut down discussion

How national HPV vaccination programs are changing the story of cervical cancer

Faster processes could push Pharmac's options for investment backlog to 400 within two years

Bellberry and ASCEPT release checklist for 'new approach methodologies' trials

Major brands and biosimilars feature prominently on November PBAC agenda